EUVIMEDEUVIMED entdecken
Crossref

Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series

Andrés Vidal González iD, Sergio López Alcázar, Rafael Escudero Tornero iD, Francisco Antonio Vergara Barria, José Ángel Amat Sánchez, Rocio Maseda Pedrero, Marta Feito Rodríguez, Raúl De Lucas Laguna

Clinical and Experimental Dermatology · 2026

DOI: 10.1093/ced/llag143 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2026. Verfasst von Andrés Vidal González und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic options for children under 12 years with severe atopic dermatitis (AD) who fail dupilumab remain limited. We retrospectively evaluated dupilumab-refractory moderate-to-severe AD treated with off-label upadacitinib in nine children. At week 24, the median Eczema Area and Severity Index (EASI) decreased from 21 to 2, with 78% achieving EASI-75. Pruritus improved rapidly (median numerical rating scale 7 to 1). Treatment was generally well tolerated, with no serious adverse events observed. These findings provide preliminary real-world evidence suggesting that Janus kinase 1 inhibition may represent a potential therapeutic option in selected paediatric patients with severe disease. Larger prospective studies are needed to confirm long-term safety and efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansAntibodies, Monoclonal, HumanizedFemaleMaleChildRetrospective StudiesChild, PreschoolSeverity of Illness IndexTreatment OutcomeOff-Label UsePruritusHeterocyclic Compounds, 3-Ring

Substanzen

Antibodies, Monoclonal, HumanizeddupilumabupadacitinibHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain.

ORCID-Profile: Andrés Vidal González, Rafael Escudero Tornero

Zitieren

APA

Vidal González, A., López Alcázar, S., Escudero Tornero, R., Vergara Barria, F. A., Amat Sánchez, J. Á., Maseda Pedrero, R., Feito Rodríguez, M., & De Lucas Laguna, R. (2026). Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llag143

Vancouver

Vidal González A, López Alcázar S, Escudero Tornero R, Vergara Barria FA, Amat Sánchez JÁ, Maseda Pedrero R, et al. Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series. Clinical and Experimental Dermatology. 2026. doi:10.1093/ced/llag143

BibTeX
@article{VidalGonzlez2026,
  author = {Vidal González, Andrés and López Alcázar, Sergio and Escudero Tornero, Rafael and Vergara Barria, Francisco Antonio and Amat Sánchez, José Ángel and Maseda Pedrero, Rocio and Feito Rodríguez, Marta and De Lucas Laguna, Raúl},
  title = {Upadacitinib in children under 12 years with dupilumab-refractory severe atopic dermatitis: a real-world case series},
  journal = {Clinical and Experimental Dermatology},
  year = {2026},
  doi = {10.1093/ced/llag143}
}
Kostenlos starten →